TRT for Low Libido: Does Testosterone Therapy Actually Restore Sex Drive?

What Testosterone Actually Does to Libido

Testosterone is the primary androgen driving sexual motivation in men. Low circulating testosterone suppresses activity in the hypothalamic regions responsible for sexual ideation, and it reduces dopaminergic tone in the mesolimbic reward pathway. The result is not just "less interest in sex." Men with hypogonadism often describe a complete absence of spontaneous sexual thoughts, a phenomenon that differs meaningfully from situational stress or relationship fatigue.

The Endocrine Society's 2018 Clinical Practice Guideline on male hypogonadism defines the diagnostic cutoff as a total testosterone below 300 ng/dL confirmed on two separate morning draws, along with at least one symptom from a recognized cluster: decreased libido, fatigue, depressed mood, reduced muscle mass, or erectile dysfunction. [1] A single low reading is insufficient, because testosterone follows a circadian rhythm that peaks between 7 and 10 a.m.

Free testosterone matters as much as total testosterone. Sex hormone-binding globulin (SHBG) binds testosterone and renders it biologically inert. A man can have a total testosterone of 380 ng/dL and still experience hypogonadal symptoms if SHBG is elevated, leaving free testosterone at, say, 45 pg/mL, well below the normal floor of 65 pg/mL. Ordering only a total testosterone panel therefore misses a meaningful subset of symptomatic men.

Androstenedione, DHEA-S, and luteinizing hormone (LH) levels help distinguish primary hypogonadism (testicular failure, elevated LH) from secondary hypogonadism (pituitary or hypothalamic dysfunction, low or normal LH), which affects treatment selection. [2]

Primary vs. Secondary Hypogonadism and Why the Distinction Matters for Treatment

Primary hypogonadism originates in the testes. Secondary hypogonadism reflects a failure upstream, at the pituitary or hypothalamus. Both produce low testosterone and low libido, but the correct treatment differs.

In primary hypogonadism, the testes cannot produce adequate testosterone regardless of signaling from the brain. Klinefelter syndrome (47,XXY), orchitis, chemotherapy-related gonadotoxicity, and physical trauma are common causes. LH and FSH are elevated because the pituitary is working overtime trying to stimulate unresponsive testes. TRT is the standard approach here. Exogenous testosterone reliably replaces what the testes cannot make. [3]

Secondary hypogonadism occurs when LH and FSH are low or inappropriately normal despite low testosterone. Causes include hyperprolactinemia, pituitary adenoma, opioid-induced androgen deficiency (OPIAD), obesity-related hypogonadism, and, in younger men who want to preserve fertility, Klinefelter and other genetic variants. For men with secondary hypogonadism who wish to remain fertile, clomiphene citrate (50 mg every other day) or human chorionic gonadotropin (hCG, 500 to 1 to 000 IU three times per week) stimulates endogenous production without suppressing spermatogenesis. TRT shuts down the hypothalamic-pituitary-gonadal (HPG) axis and causes azoospermia in most men within 3 months of initiation. [4]

Late-onset hypogonadism, sometimes called andropause, represents a gradual age-related decline in testosterone typically beginning in the mid-40s. Serum total testosterone falls roughly 1 to 2 percent per year after age 30, according to data from the Baltimore Longitudinal Study of Aging. [5] By age 70, approximately 30 percent of men meet biochemical criteria for hypogonadism. The symptom triad most predictive of a clinically meaningful testosterone deficiency is: reduced morning erections, low libido, and erectile dysfunction, as identified by the European Male Aging Study (EMAS, N=3,369). [6]

The T Trials: What the Strongest Evidence Actually Shows

The Testosterone Trials (T Trials) represent the best available evidence for TRT efficacy in older men. This was a coordinated set of seven double-blind, placebo-controlled trials conducted across 12 sites in the United States. The sexual function trial enrolled 470 men aged 65 and older with total testosterone below 275 ng/dL and self-reported sexual dysfunction.

Men randomized to testosterone gel 1% (titrated to achieve levels of 500 to 1 to 000 ng/dL) showed a statistically significant improvement in sexual desire score, sexual activity frequency, and erectile function score compared to placebo at 12 months. [7] The between-group difference in the Psychosexual Daily Questionnaire sexual desire domain was 0.58 points (P<0.001), which the investigators described as clinically meaningful.

Two important qualifications apply. First, the benefit was most pronounced in men with baseline testosterone below 200 ng/dL. Men in the 200 to 275 ng/dL range showed smaller and less consistent gains. Second, co-existing vascular disease, diabetes, or depression attenuated the libido response substantially. TRT raised desire, but physical barriers to erection required additional management with phosphodiesterase type-5 (PDE5) inhibitors such as sildenafil or tadalafil.

A 2016 meta-analysis in the Journal of Sexual Medicine pooled 14 randomized controlled trials (total N=2,298) and found that TRT significantly improved libido scores compared to placebo, with a standardized mean difference of 0.54 (95% CI 0.30 to 0.79). [8] The effect was larger in men with confirmed hypogonadism than in men with low-normal testosterone.

TRT for Erectile Dysfunction: Where It Helps and Where It Falls Short

Erectile dysfunction and low libido are separate problems that frequently coexist. Low testosterone reduces libido reliably. Its effect on the mechanical process of erection is more conditional.

Testosterone supports nitric oxide synthase activity in penile endothelium, and animal models show that castration reduces penile smooth muscle content and increases fibrosis over time. In men, severe hypogonadism (total T below 150 ng/dL) can produce an androgen-deficient state where PDE5 inhibitors work poorly because there is insufficient testosterone to sensitize the tissue to nitric oxide signaling. [9] Restoring testosterone to mid-normal range (400 to 600 ng/dL) can, in this subset, restore responsiveness to sildenafil or tadalafil.

For most men with ED and borderline-low testosterone (250 to 350 ng/dL), vascular health is the dominant factor. Atherosclerosis, hypertension, metabolic syndrome, and diabetes all impair penile arterial inflow independently of testosterone levels. TRT alone will not fix arterial insufficiency.

The American Urological Association's 2018 ED guideline notes: "Testosterone therapy is appropriate in men with sexual dysfunction and confirmed hypogonadism, as it may improve libido and response to PDE5 inhibitor therapy." [10] That phrasing captures the evidence precisely. TRT is not a standalone ED cure; it is a foundational correction that may improve the ceiling of what PDE5 inhibitors can achieve.

The HealthRX Two-Axis Framework for TRT and Sexual Dysfunction

Clinicians at HealthRX use a two-axis triage system before recommending TRT for sexual complaints:

• Axis 1: Desire deficit (libido)? If yes, check total T, free T, SHBG, LH, FSH, and prolactin. Confirmed hypogonadism with low libido is a clear TRT indication.
• Axis 2: Mechanical deficit (erection)? If yes, assess cardiovascular risk, check HbA1c, lipids, blood pressure, and penile blood flow. Treat the vascular layer first or concurrently. TRT alone rarely fixes vascular ED.

Men with both axes positive (desire AND mechanical deficit) often need TRT plus a PDE5 inhibitor, and sometimes lifestyle modification or referral to urology for further workup.

TRT for Fatigue: The Hormonal Energy Connection

Fatigue is the symptom that drives more men to check their testosterone than any other complaint. Hypogonadism reduces mitochondrial efficiency in skeletal muscle, impairs sleep architecture, and reduces erythropoiesis. The result is a layered, systemic tiredness that does not resolve with extra sleep.

A 12-week randomized trial published in the Journal of Clinical Endocrinology and Metabolism (N=138 men with testosterone below 300 ng/dL) found that testosterone undecanoate significantly improved fatigue scores, with the Multidimensional Fatigue Inventory total score improving by 8.2 points versus 2.1 points in placebo (P<0.001). [11] Lean mass also increased by 1.8 kg in the TRT group, which contributed to the functional energy improvement.

Fatigue without hypogonadism does not respond to TRT. This is a common source of patient disappointment when testosterone is prescribed for borderline-low levels without confirmed symptoms. The Endocrine Society guideline explicitly advises against TRT in men who are asymptomatic, even with biochemically low testosterone. [1]

Thyroid dysfunction, sleep apnea, anemia, and depression mimic hypogonadal fatigue precisely. A complete metabolic panel, TSH, CBC, and the Epworth Sleepiness Scale should accompany the testosterone workup before attributing fatigue to low T.

How TRT Is Prescribed and What Therapeutic Levels Look Like

The most common formulations in clinical practice are:

Testosterone cypionate or enanthate (injectable). Weekly intramuscular or subcutaneous injection of 100 to 200 mg is the most cost-effective option. Peak levels occur 24 to 48 hours post-injection; trough levels are measured just before the next injection. Target trough: 400 to 600 ng/dL. Some men prefer twice-weekly dosing (50 to 100 mg) to reduce peak-trough swings that can cause mood variability.

Testosterone gel (1% or 1.62%). Applied daily to shoulders or upper arms. Achieves more stable serum levels than weekly injections. Transfer to female partners or children via skin contact is a documented risk; hands must be washed and application sites covered before contact. FDA-approved gels include AndroGel and Testim. [12]

Testosterone pellets (Testopel). Inserted subcutaneously in the buttock every 3 to 6 months. Each pellet contains 75 mg of crystalline testosterone. A typical implant is 6 to 10 pellets. Advantages include compliance and stability; the disadvantage is that the dose cannot be adjusted once implanted.

Testosterone undecanoate (Aveed, injectable). Given as 750 mg IM at 0 weeks, 4 weeks, then every 10 weeks. FDA approval requires administration in a healthcare setting with a 30-minute observation window because of rare but serious pulmonary oil microembolism. [13]

Clomiphene citrate (25 to 50 mg oral, every other day) is an off-label option for secondary hypogonadism in men who want to preserve fertility. It stimulates endogenous production rather than replacing testosterone exogenously.

Monitoring, Safety, and Contraindications

TRT requires structured follow-up. The Endocrine Society recommends checking total testosterone (targeting mid-normal range, 400 to 700 ng/dL), hematocrit, and PSA at 3 months after initiation, then at 6 months, then annually. [1]

Erythrocytosis (hematocrit above 54%) is the most common laboratory adverse effect, occurring in 5 to 10 percent of patients. It raises viscosity and theoretical thrombotic risk. Dose reduction, dose-interval spacing, or therapeutic phlebotomy are management options.

Prostate safety has been debated for decades. The TRAVERSE trial (N=5,246, median follow-up 33 months), published in the New England Journal of Medicine in 2023, found no significant increase in prostate cancer incidence in men on TRT compared to placebo (hazard ratio 0.96 to 95% CI 0.65 to 1.41). [14] Acute urinary retention events were slightly more common in the TRT group (2.5% vs. 1.9%), which is relevant for men with existing lower urinary tract symptoms.

Cardiovascular safety was also addressed in TRAVERSE. The trial was designed as a cardiovascular outcomes study in men with or at high risk for cardiovascular disease. TRT was non-inferior to placebo for the primary MACE endpoint (major adverse cardiovascular events: cardiovascular death, nonfatal MI, nonfatal stroke) at 33 months, with MACE occurring in 7.0% of TRT recipients vs. 7.3% of placebo recipients. [14]

Absolute contraindications include active or suspected prostate cancer, male breast cancer, hematocrit above 54%, uncontrolled heart failure (NYHA class IV), and a desire for current fertility. Relative contraindications include untreated obstructive sleep apnea, lower urinary tract symptoms with IPSS score above 19, and unexplained elevations in PSA.

Starting TRT: The Clinical Intake Process

A well-structured intake avoids the most common prescribing errors. At HealthRX, the minimum required labs before initiating TRT are:

1. Two morning total testosterone measurements (drawn between 7 and 10 a.m., at least one week apart)
2. Free testosterone and SHBG
3. LH and FSH (to classify primary vs. secondary)
4. Prolactin (to rule out prolactinoma)
5. CBC, comprehensive metabolic panel
6. PSA (men over 40, or any man with urinary symptoms)
7. Estradiol (baseline, since aromatization of exogenous testosterone can raise estradiol and cause gynecomastia or fluid retention)

The Endocrine Society guideline states: "We recommend against making a diagnosis of androgen deficiency in men with acute or subacute illness." [1] Testosterone drops transiently during infection, surgery, or severe psychological stress. Testing during these windows produces false positives and unnecessary prescriptions.

Men whose total testosterone sits between 200 and 300 ng/dL with clear symptoms and low free testosterone are generally good candidates. Men with total testosterone above 400 ng/dL and nonspecific fatigue without other hypogonadal signs are unlikely to respond to TRT and carry higher risk of being disappointed.